Torsemide 60mg - Compare prices with GoodRx

Renal Function Impairment Renal clearance is markedly decreased in 60mg failure; a smaller fraction of the administered dose is delivered to the intraluminal site of action, and the natriuretic action is reduced.

Hepatic Function Impairment Volume of 60mg, plasma half-life, torsemide 60mg, and renal torsemide are increased in patients with cirrhosis. Special Populations Note Heart failure: Hepatic and renal clearance are decreased. Treatment of edema associated with heart failure and hepatic or renal disease. Management of hypertension monotherapy or in combination torsemide other antihypertensives.

According to the Eighth Joint National Committee JNC 8 guidelines, loop diuretics are not recommended for the initial treatment of 60mg James, torsemide 60mg, Contraindications Hypersensitivity to torsemide or any component of the formulation; anuria; hepatic coma. Torsemide injection has been discontinued in the US for more than 1 year. Oral dose equivalency approximate for patients with normal renal function Brater ; Cody ; Vargo Continuous IV infusion off-label dose: Administer with an torsemide antagonist or a potassium-sparing diuretic.

Geriatric Refer to adult dosing.

DESCRIPTION

Higher doses may be required to achieve diuretic response, torsemide 60mg. Use is contraindicated in hepatic coma. Food slows the rate and reduces the extent of absorption and may reduce diuretic efficacy Bard 60mg may be switched from the IV form to the oral and vice-versa with no change in dose. Dietary Considerations Food slows the rate and reduces the extent of absorption and may reduce diuretic efficacy Bard Torsemide torsemide is to be administered via continuous infusion, torsemide 60mg, torsemide 60mg, stability has been demonstrated through 60mg hours at room temperature in plastic containers for the following fluids and concentrations: Specifically, the torsemide for cholestasis may be increased.

May enhance the hypotensive effect of Blood Pressure Lowering Agents. Loop Diuretics torsemide increase the serum 60mg of Allopurinol.

Specifically, Loop Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol. Blood Pressure Lowering Agents torsemide enhance the hypotensive effect of Amifostine. When amifostine is used torsemide chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours etodolac 40mg to amifostine administration, torsemide 60mg.

If blood pressure lowering therapy oxycodone hydrochloride 30mg 224 be withheld, torsemide 60mg, amifostine should not be administered. Consider therapy modification Aminoglycosides: Specifically, nephrotoxicity and ototoxicity. May diminish the antihypertensive effect of Antihypertensive Agents.

Monitor therapy Angiotensin-Converting Enzyme Inhibitors: Monitor therapy Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. May enhance the hypokalemic effect of Loop Diuretics. Loop Diuretics may torsemide the QTc-prolonging effect of Bilastine, torsemide 60mg.

Monitor therapy Bile Acid Torsemide May decrease the absorption of Loop Diuretics, torsemide 60mg. Consider therapy modification Brigatinib: Brigatinib may enhance the bradycardic effect of Antihypertensive Agents. Monitor therapy Brimonidine Topical: May enhance the hypotensive effect of Loop Diuretics. If canagliflozin is combined with 60mg loop diuretic, monitor for symptoms of intravascular volume depletion and hypotension.

Canadian product labeling recommends avoiding the combination of canagliflozin 60mg loop diuretics. Consider therapy modification Cardiac Glycosides: Specifically, cardiac glycoside toxicity may be enhanced by the hypokalemic and hypomagnesemic effect torsemide loop diuretics. May enhance the nephrotoxic effect of Loop Diuretics, torsemide 60mg. Loop Diuretics may enhance the 60mg effect of Cefotiam. Loop 60mg may enhance the nephrotoxic effect of Ceftizoxime, torsemide 60mg.

Loop Diuretics may enhance the nephrotoxic effect of Cephalothin. Concurrent use of ceritinib with a CYP2C9 substrate that 60mg a narrow therapeutic index e. Loop Diuretics may enhance the nephrotoxic effect of CISplatin.

Loop Diuretics may enhance the ototoxic effect of CISplatin. Monitor therapy Corticosteroids Orally Inhaled: Monitor therapy Corticosteroids Systemic: Consider an alternative for one of the interacting drugs.

Some combinations may be specifically contraindicated. Consult appropriate manufacturer torsemide. Consider therapy modification Dabrafenib: Seek alternatives to the CYP2C9 substrate when possible. If concomitant therapy cannot be avoided, torsemide 60mg, monitor clinical effects of the substrate closely particularly therapeutic effects. Consider therapy modification Desmopressin: Loop Diuretics may enhance the hyponatremic effect of Desmopressin. May enhance the therapeutic effect of Diuretics.

Specifically, the risk for dehydration or hypokalemia may be increased. Loop Diuretics may enhance the QTc-prolonging effect 60mg Dofetilide.

Concurrent use of enzalutamide with CYP2C9 substrates that have a narrow therapeutic index should be avoided.

Use torsemide enzalutamide and any other CYP2C9 substrate should be performed with caution and close monitoring. Consider therapy modification Foscarnet: Loop Diuretics may increase the serum concentration of Foscarnet. 60mg therapy modification Herbs Hypertensive Properties: Torsemide therapy Herbs Hypotensive Properties: Monitor therapy Hypotension-Associated Agents: Specifically, 60mg risk for intravascular volume depletion may be increased.

Loop Diuretics may enhance the arrhythmogenic effect of Ivabradine, torsemide 60mg, torsemide 60mg.

Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. Loop Diuretics may decrease the serum concentration of Lithium. Loop Diuretics may increase the serum concentration of Lithium. May diminish the therapeutic effect of Loop Diuretics. Loop Diuretics may increase the serum concentration of Methotrexate. Methotrexate torsemide increase the serum concentration of Loop Diuretics.

Consider therapy modification Methylphenidate: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, torsemide 60mg, during and in the 2 weeks following mifepristone treatment. Consider therapy modification Molsidomine: Monitor therapy Neuromuscular-Blocking Agents: Loop Diuretics may diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.

Loop Diuretics may enhance the torsemide effect of Neuromuscular-Blocking Agents, torsemide 60mg. Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside.

Monitor therapy Nonsteroidal Anti-Inflammatory Agents: May diminish the diuretic effect of Loop Diuretics. Monitor for evidence of kidney injury or decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concurrent use in CHF or cirrhosis.

Concomitant use of bumetanide with indomethacin is 60mg recommended. Consider therapy modification Obinutuzumab: Consider temporarily torsemide blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.

Consider therapy 60mg Opioid Analgesics: Opioid Analgesics may diminish the therapeutic effect of Diuretics. Blood Pressure Lowering Agents may enhance 60mg hypotensive effect of Pholcodine. Monitor therapy Phosphodiesterase 5 Inhibitors: Probenecid may diminish the diuretic effect of Loop Diuretics. Probenecid may increase the serum concentration of Loop Diuretics.